Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
design/colorway is very similar to the peds Hep A carton; design/colorway is very similar to the peds Hep A carton which could increase the risk of vaccine administration errors; This non-serious case was reported by a non-health professional and described the occurrence of product packaging confusion in a patient who did not receive Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included HAV (Havrix) for prophylaxis. The patient did not receive Shingrix and Havrix. The patient experienced product packaging confusion (Verbatim: design/colorway is very similar to the peds Hep A carton) and circumstance or information capable of leading to medication error (Verbatim: design/colorway is very similar to the peds Hep A carton which could increase the risk of vaccine administration errors). The outcome of the product packaging confusion and circumstance or information capable of leading to medication error were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-MAR-2026 The consumer reported that design/colorway is very similar to the peds Hep A carton, which could increase the risk of vaccine administration errors. The batch number was not provided and a request for this information has been made.